<DOC>
	<DOCNO>NCT02172508</DOCNO>
	<brief_summary>The primary objective study investigate effect combine therapy 18 μg tiotropium q.d . plus pulmonary rehabilitation versus placebo plus pulmonary rehabilitation 6-minute walking distance ( 6MWD ) 7 week treatment patient moderate severe COPD . The secondary objective study include assessment effect combine therapy 18 μg Tiotropium q.d . plus rehabilitation versus placebo plus rehabilitation dyspnoea , constant work rate exercise endurance , daily activity lung volume . The third objective study investigate correlation result 6-minute walking test ( 6MWT ) , constant work rate exercise test ( CWR ) daily activity .</brief_summary>
	<brief_title>Effect Tiotropium Inhalation Capsules Exercise Tolerance , Daily Activity Dyspnoea Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Participating 3 Weeks Pulmonary Rehabilitation</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . All patient must sign Informed Consent Form consistent ICHGCP guideline prior participation trial , might include prestudy washout usual pulmonary medication restriction . 2 . All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable airway obstruction FEV1 ≤ 65 % predict normal FEV1 ≤ 70 % FVC visit 1 3 . 3 . Patients must show TGV ≥ 120 % predict normal 4 . Male female patient ≥ 40 ≤ 75 year old 5 . Patients must current exsmokers smoke history 10 packyears . 6 . Patients must able perform study related test include exercise test , acceptable pulmonary function test must able maintain record study period require protocol . 7 . Patients must able inhale medication HandiHaler® meter dose inhaler . 8 . Patients must already eligible participation pulmonary rehabilitation program per investigator 's usual criterion . 1 . Patients significant disease COPD exclude . A significant disease define disease , opinion investigator , may either put patient risk participation study disease may influence result study patient 's ability participate study . 2 . Patients clinically relevant abnormal baseline hematology , blood chemistry urinanalysis , abnormality defines disease list exclusion criterion . 3 . All patient serum glutamicoxaloacetic transaminase ( SGOT ) &gt; 80 IU/L , serum glutamicpyruvic transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dL creatinine &gt; 2.0 mg/dL exclude regardless clinical condition . 4 . Patients history asthma , allergic rhinitis atopy total blood eosinophil count &gt; 600/mm3 . A repeat eosinophil count conduct patient . 5 . Patients recent history ( i.e. , six month less ) myocardial infarction . 6 . Patients unstable lifethreatening cardiac arrhythmia , include patient newly diagnose , clinically relevant arrhythmia ECG perform visit 1 . Patients arrhythmia require intervention ( i.e . hospitalization , cardioversion , pacemaker placement , automatic implantable cardiac defibrillator ( AICD ) placement ) change drug therapy last year also exclude study . 7 . Patients hospitalized heart failure past three year . 8 . Patients know active tuberculosis . 9 . Patients history cancer within last 5 year . Patients treat basal cell carcinoma allow . 10 . Patients history cystic fibrosis , bronchiectasis , interstitial lung disease , pulmonary thromboembolic disease . 11 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion 1 . 12 . Patients respiratory infection 4 week prior screen visit recovery within 6 week prior visit 3 randomise 6 week follow recovery infection exacerbation . 13 . Patients currently pulmonary cardiac rehabilitation program complete pulmonary cardiac rehabilitation program last 6 month prior screen visit ( visit 1 ) . 14 . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system . 15 . Patients symptomatic prostatic hyperplasia bladder neck obstruction . Patients treat prostatic hyperplasia report minimal symptom may include continue medication . 16 . Patients know narrowangle glaucoma . 17 . Patients theophylline level &gt; 5.0 μg/ml . 18 . Patients currently βblocker therapy include ocular preparation . 19 . Patients treat oral betaadrenergics . 20 . Patients treated antihistamine ( H1 receptor antagonist ) asthma exclude allergic condition ( See exclusion criterion No . 4 ) . 21 . Patients use oral corticosteroid medication unstable dos ( i.e. , less 6 week stable dose ) dose excess equivalent 10 mg prednisone per day 20 mg every day . 22 . Patients treat monamine oxidase inhibitor tricyclic antidepressant . 23 . Patients treat commercially available Spiriva® within last 3 month prior visit 1 . 24 . Patients treat cromolyn sodium nedocromil sodium within 1 month visit 1 . 25 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception previous three month ( i.e. , oral contraceptive , intrauterine device , diaphragm subdermal implant e. g. : Norplant® ) . 26 . Significant alcohol drug abuse within past 5 year . 27 . Current participation clinical trial use investigational drug within one month six half life ( whichever great ) prior screen visit ( visit 1 ) . 28 . Patients use supplemental oxygen rest exclude . 29 . Patients oxygen saturation 85 % exercise despite supplemental oxygen therapy visit 1 2 excluded participation . 30 . If investigator 's opinion patient perform exercise test supplemental oxygen , supplemental oxygen therapy use follow test include rehabilitation program constant level . 31 . Patients history orthopedic , muscular neurologic disease would interfere regular participation aerobic exercise exercise testing . 32 . Patients body mass index &gt; 30 kg/m2 &lt; 18 kg/m2 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>